McIntosh/Shays hearing on FDA device program slated for June 29.
This article was originally published in The Gray Sheet
Executive Summary
MCINTOSH/SHAYS HEARING ON FDA DEVICE PROGRAM SLATED FOR JUNE 29, according to staffers. Both Congressmen serve on the House Government Reform and Oversight Committee, with Rep. David McIntosh (R-Ind.) chairing the National Economic Growth Subcommittee, and Rep. Christopher Shays (R-Conn.) heading up the Human Resources Subcommittee. Specific elements of the device program to be examined at the joint subcommittee hearing have not yet been determined, staffers say, and witnesses have not yet been scheduled.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.